GBG Research at ASCO Annual Meeting 2019

#3075: Comparison of an automated cartridge-based system for mRNA assessment with central immunohistochemistry in the neoadjuvant GeparX trial.

• Poster Session Developmental Therapeutics and Tumor Biology (Nonimmuno); Sat, Jun 01, 8:00 AM - 11:00 AM (poster)
• First author: C. Denkert, Institut für Pathologie Philipps-Universität Marburg, Germany
• Poster download
  

#1012: Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.

• Session: Clinical Science Symposium Targeting Breast Cancer: Breaking the Code; Sat, Jun 01, 3:36 PM - 3:48 PM (oral presentation)
• First author: IE. Krop, Dana-Farber Cancer Institute, Boston, MA

#509: Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial.

• Poster Discussion Session on Sunday, June 2, 2019, 4:30 PM - 6:00 PM (poster discussion)
• First author: S. Loibl, GBG Neu-Isenburg, Germany
• Poster download
  

#588: Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple-negative breast cancer patients undergoing neoadjuvant therapy with durvalumab: Results from the prospectively randomized GeparNuevo trial.

• Poster Session Breast Cancer - Local/Regional/Adjuvant; Sun, Jun 02, 8:00 AM - 11:00 AM (poster)
• First author: B. Seliger, Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
• Poster download
  

#573: Germline mutation status and therapy response in high-risk early breast cancer: Results of the GeparOcto study (NCT02125344).

• Poster Session Breast Cancer - Local/Regional/Adjuvant; Sun, Jun 02, 8:00 AM - 11:00 AM (poster)
• First author: E.Pohl-Rescigno, Center for Familial Breast and Ovarian Cancer and Center for Integrated Oncology (CIO), Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
• Poster download
  

#TPS605: NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.

• Poster Session: Breast Cancer - Local/Regional/Adjuvant; Sun, Jun 02, 8:00 AM - 11:00 AM (poster)
• First author: IE. Krop, Dana-Farber Cancer Institute, Boston, MA
• Poster download
  

#513: Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.

• Poster Discussion Session on Sunday; June 2, 2019, 4:30 PM - 6:00 PM (poster discussion)
• First author: A. Schneeweiss, National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany

#510: Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.

• Poster Discussion Session on Sunday; June 2, 2019, 8:00 AM - 11:00 AM (poster discussion)
• First author: O. Metzger, Dana-Farber Cancer Institute, Boston, MA

#506: GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).

• Session: Oral Abstract Session, Breast Cancer - Local/Regional/Adjuvant; Mon, Jun 03, 11:45 AM - 11:57 AM (oral presentation)
• First author: PA. Fasching, Department of Gynecology and Obstetrics; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
• Presentation downlaod